IRIS International Elects Edward F. Voboril to Board of Directors

CHATSWORTH, Calif.--(Business Wire)--
IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), a leading manufacturer of
automated in-vitro diagnostics systems and consumables for use in
hospitals and commercial laboratories worldwide, announced today that
Edward F. Voboril, a seasoned senior executive and director within the
medical device and healthcare industry, has been elected to the
Company's Board of Directors, expanding its board to eight members.

"Mr. Voboril's extensive career in the healthcare and technology
sectors will be invaluable as we continue the rapid growth and
extension of our core urinalysis technology platform, and as we
proceed with our new diagnostics initiatives and extensive product
pipeline," stated Cesar Garcia, Chairman, President and Chief
Executive Officer of IRIS International.

"His career encompasses nearly 20 years experience as chairman,
chief executive officer and director for mid-sized public companies,
as well as not-for-profit organizations, having served on audit,
nominating, compensation and corporate governance committees. His
skills will complement and be an asset to our current board and we
look forward to his contributions," Mr. Garcia said.

Mr. Voboril is currently Chairman of the Board of Analogic
Corporation (NASDAQ: ALOG), a leading $370 million designer and
manufacturer of advanced health and security systems and subsystems
sold primarily to Original Equipment Manufacturers (OEMs). He has been
a member of the Analogic board since 1990.

In 2008, Mr. Voboril, 65, retired as Chairman of Greatbatch, Inc.
(NYSE:GB), a technology based manufacturer of medical devices and
specialty power sources, where he served as Chief Executive Officer
from 1990 to 2006. During his tenure at Greatbatch, he led the Company
from revenues of about $30 million to $318 million in 2007 as
Greatbatch evolved from a small specialty battery manufacturer to a
world leader in the supply of precision components for implantable
medical devices. Under his leadership, Greatbatch's growth was driven
by both the development of its own proprietary technology and
complementary acquisitions.

Mr. Voboril also served as Vice President and General Manager of
the Biomedical Division of PPG Industries and held senior executive
positions in the medical businesses of Honeywell, General Electric,
Syntex and Litton Industries. In addition, from 1995 to 1998, he was
President of the Health Care Industries Association (HCIA), a
not-for-profit trade association and networking support organization
in Western New York that provides professional services for healthcare
industries and institutions.

Mr. Voboril is presently an adjunct professor of engineering and
chairman of 'NUvention' at the Center for Entrepreneurship and
Innovation at Northwestern University, and also serves on the
manufacturing council of the United States Department of Commerce. He
holds a Bachelor of Arts degree in Industrial Engineering from
Northwestern University and an MBA from Harvard University where he
was a Baker Scholar.

About IRIS International

IRIS International is a leading global in vitro diagnostics
company focused on products that analyze particles and living cell
forms and structures, or morphology of a variety of body fluids. The
Company's products leverage its strengths in flow imaging technology,
particle recognition and automation to bring efficiency to hospital
and commercial laboratories. The initial applications for its
technology have been in the urinalysis market and the Company is the
leading worldwide provider of urine microscopy systems, with an
installed based of more than 1,900 systems in over 50 countries.

SAFE HARBOR PROVISION

This press release contains forward-looking statements made in
reliance upon the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include, but
are not limited to, the Company's views on future financial
performance, market growth, capital requirements, regulatory
developments, new product introductions and acquisitions, and are
generally identified by phrases such as "thinks," "anticipates,"
"believes," "estimates," "expects," "intends," "plans," and similar
words. Forward-looking statements are not guarantees of future
performance and are inherently subject to uncertainties and other
factors which could cause actual results to differ materially from the
forward-looking statement. These statements are based upon, among
other things, assumptions made by, and information currently available
to, management, including management's own knowledge and assessment of
the Company's industry, R&D initiatives, competition and capital
requirements. Other factors and uncertainties that could affect the
Company's forward-looking statements include, among other things, the
following: identification of feasible new product initiatives,
management of R&D efforts and the resulting successful development of
new products and product platforms; obtaining regulatory approvals for
new and enhanced products; acceptance by customers of the Company's
products; integration of acquired businesses; substantial expansion of
international sales; reliance on key suppliers; the potential need for
changes in long-term strategy in response to future developments;
future advances in diagnostic testing methods and procedures;
potential changes in government regulations and healthcare policies,
both of which could adversely affect the economics of the diagnostic
testing procedures automated by the Company's products; rapid
technological change in the microelectronics and software industries;
and competitive factors, including pricing pressures and the
introduction by others of new products with similar or better
functionality than our products. These and other risks are more fully
described in the Company's filings with the Securities and Exchange
Commission, including the Company's most recently filed Annual Report
on Form 10-K and Quarterly Report on Form 10-Q, which should be read
in conjunction herewith for a further discussion of important factors
that could cause actual results to differ materially from those in the
forward-looking statements. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

IRIS International
Cesar Garcia, 818-709-1244, x 7123
Chairman and Chief Executive Officer
or
The Wall Street Group, Inc.
Ron Stabiner, 212-888-4848

Copyright Business Wire 2008